WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice

Connexin32 (Cx32) is the major gap junction forming protein in liver and lack of functional Cx32 enhances hepatocarcinogenesis. Many tumour-promoting agents block gap junctional intercellular communication, which may favour clonal expansion of neoplastic cells. We recently demonstrated that liver tu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 2003-09, Vol.24 (9), p.1561-1565
Hauptverfasser: Moennikes, Oliver, Stahl, Sabine, Bannasch, Peter, Buchmann, Albrecht, Schwarz, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1565
container_issue 9
container_start_page 1561
container_title Carcinogenesis (New York)
container_volume 24
creator Moennikes, Oliver
Stahl, Sabine
Bannasch, Peter
Buchmann, Albrecht
Schwarz, Michael
description Connexin32 (Cx32) is the major gap junction forming protein in liver and lack of functional Cx32 enhances hepatocarcinogenesis. Many tumour-promoting agents block gap junctional intercellular communication, which may favour clonal expansion of neoplastic cells. We recently demonstrated that liver tumourigenesis is accelerated in Cx32-wild-type but not in Cx32-null mice by the model tumour promoter phenobarbital (PB). In the present study, male Cx32-wild-type and Cx32-null mice were treated with a single injection of 90 µg/g body wt of N-nitrosodiethylamine (DEN) at 6 weeks of age and were subsequently kept on a diet containing the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) or on control diet. Thirty-eight weeks after DEN treatment, mice were killed, frozen liver sections were prepared and (pre)-neoplastic lesions were identified by alterations in glucose-6-phosphatase (G-6-Pase) and glutamine synthetase (GS) staining. G-6-Pase-deficient lesions were generally small in size and were observed in all groups of mice. Large focal pre-neoplastic and benign neoplastic lesions, however, which demonstrated increased rather than decreased activity in G-6-Pase were exclusively present in DEN/Wy-14,643-treated mice. G-6-Pase-positive lesions were strongly promoted by Wy-14,643, both in Cx32-wild-type and Cx32-null mice without significant difference in response between mice of the two genotypes. This contrasts G-6-Pase-negative lesions and lesions over-expressing GS, which were both increased by WY-14,643 treatment in number and size in Cx32-wild-type but not in Cx32-null mice. GS-positive lesions from WY-14,643-treated mice harboured β-catenin mutations, a hallmark of lesions selected during promotion by PB, while G-6-Pase-positive lesions, which displayed negative or diffuse GS staining, did not show β-catenin mutations. Our results demonstrate significant differences between mouse liver lesions of differing phenotype and genotype in their response towards selection by Wy-14,643 during the promotional phase of hepatocarcinogenesis.
doi_str_mv 10.1093/carcin/bgg099
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18887175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>423550091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-51a9750a249a28eda42fc33cce046e83f6e9720114a078814aff219a3df93cd23</originalsourceid><addsrcrecordid>eNpdkEFv1DAQRi0EokvhyBVFSHDC1GM7iX2EClpEERdQgYvlOuPFJbEXOxHtv8coKxZxmsM8fd_MI-QxsJfAtDhxNrsQT662W6b1HbIB2THKQbG7ZMNACiqEkEfkQSnXjEEnWn2fHAFXoEH1G4KXXynIF10FJxyCnXFodjlNaQ4pNsk333Fn57S2pC1GLKE0ITYuxYg3IQpOf4VxoPPtDhsbh38XcRnHZgoOH5J73o4FH-3nMfn89s2n03N68fHs3emrC-oktDNtweq-ZZZLbbnCwUrunRDOIZMdKuE71D1nANKyXqk6vOegrRi8Fm7g4pg8X3PrCz8XLLOZQnE4jjZiWooBpVQPfVvBp_-B12nJsd5mamCVBFxXiK6Qy6mUjN7scphsvjXAzB_5ZtViVvmVf7IPXa6qzAO9t12BZ3vAFmdHn210oRy4FkAzzg7Focx483dv8w_T9aJvzfmXb-asVd371-zSfBC_ASknnIo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219359129</pqid></control><display><type>article</type><title>WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Moennikes, Oliver ; Stahl, Sabine ; Bannasch, Peter ; Buchmann, Albrecht ; Schwarz, Michael</creator><creatorcontrib>Moennikes, Oliver ; Stahl, Sabine ; Bannasch, Peter ; Buchmann, Albrecht ; Schwarz, Michael</creatorcontrib><description>Connexin32 (Cx32) is the major gap junction forming protein in liver and lack of functional Cx32 enhances hepatocarcinogenesis. Many tumour-promoting agents block gap junctional intercellular communication, which may favour clonal expansion of neoplastic cells. We recently demonstrated that liver tumourigenesis is accelerated in Cx32-wild-type but not in Cx32-null mice by the model tumour promoter phenobarbital (PB). In the present study, male Cx32-wild-type and Cx32-null mice were treated with a single injection of 90 µg/g body wt of N-nitrosodiethylamine (DEN) at 6 weeks of age and were subsequently kept on a diet containing the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) or on control diet. Thirty-eight weeks after DEN treatment, mice were killed, frozen liver sections were prepared and (pre)-neoplastic lesions were identified by alterations in glucose-6-phosphatase (G-6-Pase) and glutamine synthetase (GS) staining. G-6-Pase-deficient lesions were generally small in size and were observed in all groups of mice. Large focal pre-neoplastic and benign neoplastic lesions, however, which demonstrated increased rather than decreased activity in G-6-Pase were exclusively present in DEN/Wy-14,643-treated mice. G-6-Pase-positive lesions were strongly promoted by Wy-14,643, both in Cx32-wild-type and Cx32-null mice without significant difference in response between mice of the two genotypes. This contrasts G-6-Pase-negative lesions and lesions over-expressing GS, which were both increased by WY-14,643 treatment in number and size in Cx32-wild-type but not in Cx32-null mice. GS-positive lesions from WY-14,643-treated mice harboured β-catenin mutations, a hallmark of lesions selected during promotion by PB, while G-6-Pase-positive lesions, which displayed negative or diffuse GS staining, did not show β-catenin mutations. Our results demonstrate significant differences between mouse liver lesions of differing phenotype and genotype in their response towards selection by Wy-14,643 during the promotional phase of hepatocarcinogenesis.</description><identifier>ISSN: 0143-3334</identifier><identifier>ISSN: 1460-2180</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgg099</identifier><identifier>PMID: 12819187</identifier><identifier>CODEN: CRNGDP</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Biological and medical sciences ; Carcinogenesis, carcinogens and anticarcinogens ; Carcinogens ; Chemical agents ; Cocarcinogenesis ; connexin32 ; Connexins - genetics ; Connexins - physiology ; Cx32 ; DEN ; G-6-Pase ; Gap Junction beta-1 Protein ; glucose-6-phosphatase ; glutamine synthetase ; Liver Neoplasms, Experimental - chemically induced ; Liver Neoplasms, Experimental - genetics ; Liver Neoplasms, Experimental - metabolism ; Male ; Medical sciences ; Mice ; Mice, Inbred C3H ; Mice, Mutant Strains ; Mutation ; N-nitrosodiethylamine ; phenobarbital ; Pyrimidines - toxicity ; Tumors</subject><ispartof>Carcinogenesis (New York), 2003-09, Vol.24 (9), p.1561-1565</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Sep 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-51a9750a249a28eda42fc33cce046e83f6e9720114a078814aff219a3df93cd23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15119020$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12819187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moennikes, Oliver</creatorcontrib><creatorcontrib>Stahl, Sabine</creatorcontrib><creatorcontrib>Bannasch, Peter</creatorcontrib><creatorcontrib>Buchmann, Albrecht</creatorcontrib><creatorcontrib>Schwarz, Michael</creatorcontrib><title>WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>Connexin32 (Cx32) is the major gap junction forming protein in liver and lack of functional Cx32 enhances hepatocarcinogenesis. Many tumour-promoting agents block gap junctional intercellular communication, which may favour clonal expansion of neoplastic cells. We recently demonstrated that liver tumourigenesis is accelerated in Cx32-wild-type but not in Cx32-null mice by the model tumour promoter phenobarbital (PB). In the present study, male Cx32-wild-type and Cx32-null mice were treated with a single injection of 90 µg/g body wt of N-nitrosodiethylamine (DEN) at 6 weeks of age and were subsequently kept on a diet containing the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) or on control diet. Thirty-eight weeks after DEN treatment, mice were killed, frozen liver sections were prepared and (pre)-neoplastic lesions were identified by alterations in glucose-6-phosphatase (G-6-Pase) and glutamine synthetase (GS) staining. G-6-Pase-deficient lesions were generally small in size and were observed in all groups of mice. Large focal pre-neoplastic and benign neoplastic lesions, however, which demonstrated increased rather than decreased activity in G-6-Pase were exclusively present in DEN/Wy-14,643-treated mice. G-6-Pase-positive lesions were strongly promoted by Wy-14,643, both in Cx32-wild-type and Cx32-null mice without significant difference in response between mice of the two genotypes. This contrasts G-6-Pase-negative lesions and lesions over-expressing GS, which were both increased by WY-14,643 treatment in number and size in Cx32-wild-type but not in Cx32-null mice. GS-positive lesions from WY-14,643-treated mice harboured β-catenin mutations, a hallmark of lesions selected during promotion by PB, while G-6-Pase-positive lesions, which displayed negative or diffuse GS staining, did not show β-catenin mutations. Our results demonstrate significant differences between mouse liver lesions of differing phenotype and genotype in their response towards selection by Wy-14,643 during the promotional phase of hepatocarcinogenesis.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>Carcinogens</subject><subject>Chemical agents</subject><subject>Cocarcinogenesis</subject><subject>connexin32</subject><subject>Connexins - genetics</subject><subject>Connexins - physiology</subject><subject>Cx32</subject><subject>DEN</subject><subject>G-6-Pase</subject><subject>Gap Junction beta-1 Protein</subject><subject>glucose-6-phosphatase</subject><subject>glutamine synthetase</subject><subject>Liver Neoplasms, Experimental - chemically induced</subject><subject>Liver Neoplasms, Experimental - genetics</subject><subject>Liver Neoplasms, Experimental - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Mice, Mutant Strains</subject><subject>Mutation</subject><subject>N-nitrosodiethylamine</subject><subject>phenobarbital</subject><subject>Pyrimidines - toxicity</subject><subject>Tumors</subject><issn>0143-3334</issn><issn>1460-2180</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEFv1DAQRi0EokvhyBVFSHDC1GM7iX2EClpEERdQgYvlOuPFJbEXOxHtv8coKxZxmsM8fd_MI-QxsJfAtDhxNrsQT662W6b1HbIB2THKQbG7ZMNACiqEkEfkQSnXjEEnWn2fHAFXoEH1G4KXXynIF10FJxyCnXFodjlNaQ4pNsk333Fn57S2pC1GLKE0ITYuxYg3IQpOf4VxoPPtDhsbh38XcRnHZgoOH5J73o4FH-3nMfn89s2n03N68fHs3emrC-oktDNtweq-ZZZLbbnCwUrunRDOIZMdKuE71D1nANKyXqk6vOegrRi8Fm7g4pg8X3PrCz8XLLOZQnE4jjZiWooBpVQPfVvBp_-B12nJsd5mamCVBFxXiK6Qy6mUjN7scphsvjXAzB_5ZtViVvmVf7IPXa6qzAO9t12BZ3vAFmdHn210oRy4FkAzzg7Focx483dv8w_T9aJvzfmXb-asVd371-zSfBC_ASknnIo</recordid><startdate>20030901</startdate><enddate>20030901</enddate><creator>Moennikes, Oliver</creator><creator>Stahl, Sabine</creator><creator>Bannasch, Peter</creator><creator>Buchmann, Albrecht</creator><creator>Schwarz, Michael</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20030901</creationdate><title>WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice</title><author>Moennikes, Oliver ; Stahl, Sabine ; Bannasch, Peter ; Buchmann, Albrecht ; Schwarz, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-51a9750a249a28eda42fc33cce046e83f6e9720114a078814aff219a3df93cd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>Carcinogens</topic><topic>Chemical agents</topic><topic>Cocarcinogenesis</topic><topic>connexin32</topic><topic>Connexins - genetics</topic><topic>Connexins - physiology</topic><topic>Cx32</topic><topic>DEN</topic><topic>G-6-Pase</topic><topic>Gap Junction beta-1 Protein</topic><topic>glucose-6-phosphatase</topic><topic>glutamine synthetase</topic><topic>Liver Neoplasms, Experimental - chemically induced</topic><topic>Liver Neoplasms, Experimental - genetics</topic><topic>Liver Neoplasms, Experimental - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Mice, Mutant Strains</topic><topic>Mutation</topic><topic>N-nitrosodiethylamine</topic><topic>phenobarbital</topic><topic>Pyrimidines - toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moennikes, Oliver</creatorcontrib><creatorcontrib>Stahl, Sabine</creatorcontrib><creatorcontrib>Bannasch, Peter</creatorcontrib><creatorcontrib>Buchmann, Albrecht</creatorcontrib><creatorcontrib>Schwarz, Michael</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moennikes, Oliver</au><au>Stahl, Sabine</au><au>Bannasch, Peter</au><au>Buchmann, Albrecht</au><au>Schwarz, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2003-09-01</date><risdate>2003</risdate><volume>24</volume><issue>9</issue><spage>1561</spage><epage>1565</epage><pages>1561-1565</pages><issn>0143-3334</issn><issn>1460-2180</issn><eissn>1460-2180</eissn><coden>CRNGDP</coden><abstract>Connexin32 (Cx32) is the major gap junction forming protein in liver and lack of functional Cx32 enhances hepatocarcinogenesis. Many tumour-promoting agents block gap junctional intercellular communication, which may favour clonal expansion of neoplastic cells. We recently demonstrated that liver tumourigenesis is accelerated in Cx32-wild-type but not in Cx32-null mice by the model tumour promoter phenobarbital (PB). In the present study, male Cx32-wild-type and Cx32-null mice were treated with a single injection of 90 µg/g body wt of N-nitrosodiethylamine (DEN) at 6 weeks of age and were subsequently kept on a diet containing the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) or on control diet. Thirty-eight weeks after DEN treatment, mice were killed, frozen liver sections were prepared and (pre)-neoplastic lesions were identified by alterations in glucose-6-phosphatase (G-6-Pase) and glutamine synthetase (GS) staining. G-6-Pase-deficient lesions were generally small in size and were observed in all groups of mice. Large focal pre-neoplastic and benign neoplastic lesions, however, which demonstrated increased rather than decreased activity in G-6-Pase were exclusively present in DEN/Wy-14,643-treated mice. G-6-Pase-positive lesions were strongly promoted by Wy-14,643, both in Cx32-wild-type and Cx32-null mice without significant difference in response between mice of the two genotypes. This contrasts G-6-Pase-negative lesions and lesions over-expressing GS, which were both increased by WY-14,643 treatment in number and size in Cx32-wild-type but not in Cx32-null mice. GS-positive lesions from WY-14,643-treated mice harboured β-catenin mutations, a hallmark of lesions selected during promotion by PB, while G-6-Pase-positive lesions, which displayed negative or diffuse GS staining, did not show β-catenin mutations. Our results demonstrate significant differences between mouse liver lesions of differing phenotype and genotype in their response towards selection by Wy-14,643 during the promotional phase of hepatocarcinogenesis.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12819187</pmid><doi>10.1093/carcin/bgg099</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 2003-09, Vol.24 (9), p.1561-1565
issn 0143-3334
1460-2180
1460-2180
language eng
recordid cdi_proquest_miscellaneous_18887175
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Animals
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
Carcinogens
Chemical agents
Cocarcinogenesis
connexin32
Connexins - genetics
Connexins - physiology
Cx32
DEN
G-6-Pase
Gap Junction beta-1 Protein
glucose-6-phosphatase
glutamine synthetase
Liver Neoplasms, Experimental - chemically induced
Liver Neoplasms, Experimental - genetics
Liver Neoplasms, Experimental - metabolism
Male
Medical sciences
Mice
Mice, Inbred C3H
Mice, Mutant Strains
Mutation
N-nitrosodiethylamine
phenobarbital
Pyrimidines - toxicity
Tumors
title WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A51%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WY-14,643-mediated%20promotion%20of%20hepatocarcinogenesis%20in%20connexin32-wild-type%20and%20connexin32-null%20mice&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Moennikes,%20Oliver&rft.date=2003-09-01&rft.volume=24&rft.issue=9&rft.spage=1561&rft.epage=1565&rft.pages=1561-1565&rft.issn=0143-3334&rft.eissn=1460-2180&rft.coden=CRNGDP&rft_id=info:doi/10.1093/carcin/bgg099&rft_dat=%3Cproquest_cross%3E423550091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219359129&rft_id=info:pmid/12819187&rfr_iscdi=true